Related Experiment Videos
Cytochrome oxidase deficiency in Alzheimer's disease
W D Parker1, C M Filley, J K Parks
1Department of Neurology, School of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Abstract:
We assayed cytochrome oxidase and other electron transport chain activities in platelet mitochondria isolated from patients with Alzheimer's disease (AD). Five of 6 patients had striking reductions of platelet cytochrome oxidase activity (patient mean, 83.72 +/- 82.99 nmol/min/mg; control mean, 167.14 +/- 36.21 nmol/min/mg; n = 8). Other electron transport chain catalytic activities were not significantly different than control values. AD may be a systemic illness, a primary defect in cytochrome oxidase may be pathogenically important in its production, and the mitochondrial genes encoding cytochrome oxidase subunits may be important in producing the defect.
Insights
Alzheimer's disease (AD) patients show significantly reduced platelet cytochrome oxidase activity. This suggests a potential systemic issue and a key role for mitochondrial defects in AD pathogenesis.
Area of Science:
- Biochemistry
- Neuroscience
- Mitochondrial Biology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Mitochondrial dysfunction is increasingly implicated in AD pathogenesis.
- Platelets offer a accessible model for studying cellular defects in AD.
Purpose of the Study:
- To investigate electron transport chain (ETC) enzyme activities, specifically cytochrome oxidase, in platelet mitochondria from AD patients.
- To explore the potential role of mitochondrial defects in the systemic pathology of AD.
Main Methods:
- Isolation of platelet mitochondria from patients diagnosed with Alzheimer's disease and healthy controls.
- Assay of cytochrome oxidase activity and other electron transport chain enzyme activities.
Main Results:
- Five out of six Alzheimer's disease patients exhibited markedly reduced platelet cytochrome oxidase activity compared to controls.
- No significant differences were observed in other measured electron transport chain enzyme activities between AD patients and controls.
- Mean cytochrome oxidase activity was substantially lower in AD patients (83.72 +/- 82.99 nmol/min/mg) versus controls (167.14 +/- 36.21 nmol/min/mg).
Conclusions:
- Reduced platelet cytochrome oxidase activity may serve as a biomarker for Alzheimer's disease.
- A primary defect in cytochrome oxidase could be pathogenically significant in AD development.
- Mitochondrial genes encoding cytochrome oxidase subunits are potential candidates for investigation in AD etiology.